4.7 Article

The natural history and treatment outcome of blast phase BCR-ABL(-) myeloproliferative neoplasms

Related references

Note: Only part of the references are listed.
Review Medicine, General & Internal

Molecular origins of cancer: Oncogenes and cancer

Carlo M. Croce

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Review Multidisciplinary Sciences

An oncogene-induced DNA damage model for cancer development

Thanos D. Halazonetis et al.

SCIENCE (2008)

Article Medicine, General & Internal

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

Linda M. Scott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Hematology

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis

David S. Snyder et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)

Article Medicine, General & Internal

MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia

Yana Pikman et al.

PLOS MEDICINE (2006)

Article Medicine, General & Internal

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

EJ Baxter et al.

LANCET (2005)

Article Hematology

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia

A Tefferi et al.

BRITISH JOURNAL OF HAEMATOLOGY (2001)

Article Medicine, General & Internal

Genomic aberrations and survival in chronic lymphocytic leukemia.

H Döhner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2000)